Back to top
more

Caribou Biosciences (CRBU)

(Delayed Data from NSDQ)

$2.68 USD

2.68
2,467,946

-0.10 (-3.60%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $2.68 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Caribou Biosciences, Inc. (CRBU) Just Overtook the 200-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment

by Zacks Equity Research

Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.

Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

How Much Upside is Left in Caribou Biosciences, Inc. (CRBU)? Wall Street Analysts Think 316.72%

by Zacks Equity Research

The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 316.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

by Zacks Equity Research

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 4.17% and 2.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 3.23% and 38.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of -24.32% and 48.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.